SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is gaining significant traction following its corporate outlook, highlighting triple-digit growth for its AI back pain platform, a debt-free balance sheet with substantial cash, and expanding commercial reach. The community is actively debating the stock's exceptionally low share float and high cash-per-share value, anticipating a potential short squeeze and sustained upward momentum. However, some market participants express caution regarding historical volatility and perceived manipulation as volume surges around key price points.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive (FLYX) is captivating market attention after being named an authorized Starlink Aviation dealer, signaling its entry into providing high-speed in-flight connectivity for private jets. This development has sparked extensive community discussion about potential short squeezes, massive trading volume, and the strategic expansion into MRO services. Traders are now evaluating whether this aerospace collaboration can sustain its impressive momentum amidst widespread bullish sentiment and ongoing volatility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending sharply higher following President Trump's positive remarks after a meeting with CEO Lip-Bu Tan, emphasizing Intel's new US-made sub-2nm CPU processor and a significant government deal, fueling community optimism about major contracts and chip manufacturing onshoring. The market is also abuzz with speculation regarding potential partnerships with tech giants and the strong performance claims for Intel's new Core Ultra Series 3 "Panther Lake" chips built on the advanced 18A process, reinforcing the company's turnaround narrative.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to its recent inclusion in the S&P MidCap 400 index, sparking anticipation of significant institutional buying. The community is actively discussing the company's strong financial position and its strategic pivot into Agentic AI orchestration, with many viewing it as an undervalued leader in the expanding automation sector despite ongoing debates about recent insider selling.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is generating significant buzz due to its aggressive pipeline expansion, highlighted by ongoing acquisition talks for promising biotechs like Revolution Medicines and its recent purchase of Cidara Therapeutics for an innovative flu treatment. The community sees these strategic moves, alongside positive data for new drugs like its oral cholesterol inhibitor and bladder cancer combo therapy, as Merck proactively addressing its impending Keytruda patent cliff. Investors are closely watching how these efforts position the pharmaceutical giant for sustained future growth.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending amid a recent announcement regarding the conversion of convertible debt to equity, prompting intense and divided community discussion. Many traders are actively anticipating a massive short squeeze, citing high cost-to-borrow and limited share availability, with expectations of significant price appreciation. Conversely, others express caution, highlighting potential dilution and the stock's inherent volatility as key concerns, reflecting a speculative market battle.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as it initiates a substantial EV-related writedown and a strategic pivot from aggressive electric vehicle expansion amid cooling market demand. This move is being interpreted by the community as a pragmatic "EV demand reset," with discussions highlighting the company's renewed capital discipline and recent analyst upgrades that are tempering concerns over job cuts and controversial software changes.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming its sonelokimab therapy can proceed with a Biologics License Application for hidradenitis suppurativa without additional clinical trials. The community is actively discussing the potential for significant analyst price target upgrades and renewed buyout speculation, with many anticipating a substantial increase from current levels. Despite volatile trading, investors see this de-risked regulatory pathway as a strong catalyst for future appreciation, especially with an Investor Day announced for February.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to recently updated revenue guidance for DefenCath extending into 2026 and 2027, which has unfortunately overshadowed the release of strong real-world evidence data for the product and its ongoing diversification through the Melinta acquisition. The community is sharply divided, with many expressing deep disappointment and accusations of mismanagement, while others view the resulting market reaction as an overdone sell-off and a significant buying opportunity for the company's long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
